Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using ,,, an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier ,,, Software Package
Mark R. Kagan 1 Julian Phillips 2 Carrie Liu 3 1Thermo Finnigan Piscataway NJ; 2Thermo Finnigan San Jose CA; 3Eisai Research Institute Andover MA Chemical Structure Validation The data presented here can be ac
Mark R. Kagan
1, Julian Phillips
2,
Carrie Liu
3
1Thermo Finnigan, Piscataway, NJ;
2Thermo Finnigan, San Jose, CA;
3Eisai Research Institute, Andover, MA
Chemical Structure Validation
The data presented here can be acquired using the Thermo Finnigan LCQ Series
of ion trap mass spectrometers
Introduction
With the high cost of bringing new drugs to market, the number of candidates
a pharmaceutical company can develop is limited. Most are using increasingly
sophisticated screening techniques to eliminate poor candidates early in
the discovery process. To be successful, properties such as the adsorption,
distribution, metabolism, excretion and toxicity of compounds, their metabolites
and impurities must be assessed quickly and accurately to characterize potential
lead compounds.
High-throughput analysis of impurities is particularly challenging at the
low sample concentrations typical in biological matrices. The wide range
of possible modifications further complicates data interpretation. With
inherent high sensitivity, selectivity, and sophisticated Data Dependent
operational capabilities, the Thermo Finnigan LCQ Series of ion trap mass
spectrometers are well suited for applications involving impurities.
Rapid acquisition, interpretation and analysis of structural data is crucial
for maintaining a compound screening process capable of working in a combinatorial
environment. Mass Frontier, Thermo Finnigans pioneering software package
for interpretation and management of mass spectra, can be configured to
automatically predict fragmentation pa
'"/>Source:
Page: All 1 2 3 4 5 6 7 8 9 Related biology technology :1.
Practical Applications of HyperDSC in a Pharmaceutical Laboratory2.
World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition3.
Low Abundance cDNA Cloned Using Stratagenes Human Universal
cDNA Library4.
Oil-Free PCR Using the Hot Top Assembly5.
Functional Cloning Using
ViraPort Retroviral cDNA Expression Libraries6.
Signal Transduction Reporting Systems Using Cis-Acting Enhancer
Elements7.
Using XL1-Red Mutator Strain to Generate Esterase Variants8.
Detect Released Oligosaccharides Using the Eagle Eye II
Still Video Imaging System9.
Comparison of Growth Techniques and Media for the Purpose of Plasmid
Isolation from E. coli Using the Eppendorf
Perfectprep Plasmid Mini
Kit10.
Genomic DNA Extraction from Buccal Swabs Using the Perfect gDNA Blood
Mini Kit11.
Genomic DNA Extraction from Buffy Coat Using the Perfect gDNA Blood
Mini Kit
(Date:9/8/2008)... Funds to Support Clinical Development of Carfi...d of Directors, SOUTH SAN FRANCISCO, Calif., Sept...he discovery and development of novel therapeutics...r and autoimmune diseases, today,announced the suc...,million. The Series C round was led by new invest...
(Date:9/8/2008)... Symphony Management Consulting a...tions Director. , Charlot...consulting.com [Symphony Management Consulting] a...tions Director., , , , ,Mr. Whalen joins Symphony...e was responsible for designing, developing, and p...
(Date:9/5/2008)...ASSAS, Va. -- With the publication of a study led ...University,s Department of Molecular and Microbiol...nderstanding how the human immunodeficiency virus ...ich is caused by HIV, affected more than 33 millio...th Organization statistics. , In the Sept. 5 iss...
(Date:9/5/2008)...terials have exercised as much of a hold on the hu... , But for all of its popular uses money, medal...t lay hidden until the 1980s, when Masatake Haruta...t gold, which had long been considered inactive, c...emonstrated the low-temperature oxidation of CO an...
Breaking Biology Technology:Proteolix Raises $79 Million in Series C Financing 2Proteolix Raises $79 Million in Series C Financing 3Symphony Managemnt Consulting Hires New Solutions Director 2Researchers decode viral process that prepares cells for HIV infection 2Scientists peel away the mystery behind gold's catalytic prowess 2Scientists peel away the mystery behind gold's catalytic prowess 3Scientists peel away the mystery behind gold's catalytic prowess 4...Neurognostics, Inc. , a Wisconsin company speciali...I) products and services, has been honored with a ...tanding Achievements. , ,Last year Neurognostics r...ch (SBIR) Grant from the National Institutes of He...RI-based biomarkers in Parkinson,s disease. Neurog...
... GE Healthcare,s LightSpeed VCT, the world,s firs...gnized today by the Wall Street Journal in the M... Technology Innovation Awards. The annual awards r...s, companies and organizations around the world in...e Wall Street Journal received approximately 750 a...
...rent Energy Systems, Inc. announced today that Dr...Dr. Raman is President of Protium Energy Technolo...gen, fuel cells and alternative energy, based in A..., Inc., is developing Aqueous Phase Reforming (APR...fuel gases and other high value chemicals. APR us...
... Wis.— Renaissance Learning , Inc., a provi...ring tools for pre-K-12 schools and districts, wil...raining and certification office center for all Re...also plans to adjust space needs at other faciliti...s Wisconsin Rapids operation. , ,As part of its Al...
Other Biology Technology:(Date:9/8/2008)...lif., September 8, 2008For allergy sufferers, the ...without pets or curtains or anything that could tr... extends its Anywhere® product line with the l...abric Spray, a new product to help manage indoor a...rox® Anywhere® Anti-Allergen Fabric Spray ...
(Date:9/8/2008)..., September 2, 2008 -- A new interactive web lesso...raduate students how herbicides are developed. The...te University, has the seal of approval by the Jo...tion and is published in the 2008 issue. , Surp...et today were discovered by random searching. Coll...
(Date:9/7/2008)...s ability to sweat may do more than keep the body ...ise-induced asthma (EIA), a common respiratory con...ing in the September issue of CHEST, the peer-re...ysicians (ACCP), shows that athletes with EIA prod...o not have breathing problems. , Warren Lockett...
(Date:9/7/2008)...A Even closely related plants produce their own n...ed to the individual plant,s specific habitat. Com...e, researchers at the Salk Institute for Biologica...a key enzyme are enough to shift the whole output ...hanges led to a mixture of henbane and tobacco-spe...
Breaking Biology News(10 mins):The Clorox Company's new indoor allergen product reduces common indoor allergens up to 90 percent 2Athletes' 'sweat and tears' linked to asthma 2Athletes' 'sweat and tears' linked to asthma 3How plants fine tune their natural chemical defenses 2How plants fine tune their natural chemical defenses 3Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 1Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 2Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 3Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 4Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 5Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 6Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 7Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients 1587 1Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients 1587 2Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients 1587 3VaxGen Issues Rebuttal to MedCap Letter 4156 1VaxGen Issues Rebuttal to MedCap Letter 4156 2VaxGen Issues Rebuttal to MedCap Letter 4156 3VaxGen Issues Rebuttal to MedCap Letter 4156 4VaxGen Issues Rebuttal to MedCap Letter 4156 5VaxGen Issues Rebuttal to MedCap Letter 4156 6VaxGen Issues Rebuttal to MedCap Letter 4156 7VaxGen Issues Rebuttal to MedCap Letter 4156 8VaxGen Issues Rebuttal to MedCap Letter 4156 9VaxGen Issues Rebuttal to MedCap Letter 4156 10VaxGen Issues Rebuttal to MedCap Letter 4156 11Tempo Participacoes S A Announces Increase of 16 8 25 in Net Revenue and of 46 3 25 in EBITDA for 2007 15024 1The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system.
4',6-Diamidino-2-phenylindole, dihydrochloride (DAPI)
...ations. The cell has a six-gel capacity with effic...-cell can be customized for several parameters: ge...system. The PROTEAN II xi multi-cell can also be c...er format that accommodates 17 and 18 cm IPG strip...
...very process in mind. Due to its in-built flexibil...eal instrument to bridge the gap between assay dev...a fully modular monochromator-based microplate det...tection techniques. In assay development, which re...
Biology Products: